Curie.Bio

Drug Discovery

Tesseract Medical Research is a biotechnology and medical sciences business focused on delivering nutrition to meet unmet needs.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Thrive Earlier Detection is a healthcare company dedicated to saving lives through early detection of cancer. It develops CancerSEEK, a liquid biopsy test designed to identify various cancers in their earliest stages via blood analysis.

Astoria Biologica is developing novel therapies for multiple sclerosis

Decrypt Biomedicine is a biotechnology company focused on the development of small-molecule drugs that target cryptic binding sites on proteins. By identifying and leveraging these previously overlooked sites, the company aims to create innovative therapeutic solutions. Currently, Decrypt Biomedicine is operating in stealth mode, indicating a strategic approach to research and development while concealing its specific projects and advancements. The company's unique focus on cryptic binding sites positions it at the forefront of drug discovery, potentially leading to breakthroughs in treating various diseases.

Differentiated Therapeutics designs and develops disease-modifying targeted protein degradation therapies for patients with unmet medical needs. It operates an AI-driven drug discovery platform that uses proprietary computational design tools and preclinical research expertise to create novel therapeutics for cancer and other serious diseases, enabling pharmaceutical and biotechnology companies to accelerate the development of targeted treatments.

Founded in 2019 and based in Cambridge, Massachusetts, MoMa Therapeutics discovers precision medicines by targeting molecular machines underlying human diseases. The company's platform enables drug development from previously intractable enzyme classes.

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.